Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal.

Ali Al-JanabiZ K Jabbar-LopezC E M GriffithsZenas Zee Ngai Yiu

Published in: The British journal of dermatology (2019)

Gordon et al. conclude that risankizumab has a higher efficacy than placebo and ustekinumab in the treatment of moderate-to-severe chronic plaque psoriasis, and that the adverse-event profiles were similar across all treatment groups.

Keyphrases

coronary artery disease
emergency department
early onset
high intensity
double blind
open label
phase iii